Recursion Pharmaceuticals, Inc. (RXRX)
Health Care ยท Biological Products, (No Diagnostic Substances)
Recursion Pharmaceuticals, Inc. (RXRX) is listed on Nasdaq, where its shares have traded since April 16, 2021. SentiSense covers Recursion Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Najat Khan is its chief executive officer. The company reports 600 employees, and its corporate website is www.recursion.com.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Latest reported results
Recursion Pharmaceuticals, Inc. reported revenue of $18.6 million for Q3 FY2026, up 258.5% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 333 institutions reported holding RXRX, with 361.9 million shares worth $1.3 billion in aggregate. The largest reported holders were Vanguard, BlackRock and ARK Invest. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on RXRX
- RXRX sentiment: whether news and social coverage of Recursion Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- RXRX ownership: all 333 reporting institutions, plus insider and congressional trades.
- RXRX financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Recursion Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Recursion Pharmaceuticals, Inc. do?
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
What sector is RXRX in?
SentiSense classifies Recursion Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does RXRX stock trade?
Recursion Pharmaceuticals, Inc. (RXRX) is listed on Nasdaq, where its shares have traded since April 16, 2021.
Who is the CEO of Recursion Pharmaceuticals, Inc.?
Najat Khan is the chief executive officer of Recursion Pharmaceuticals, Inc..